Low libido in women: is testosterone really the missing piece?
Quick answer
Bokody's video claims female arousal has 'almost nothing' to do with hormones and that emotional context from a partner can reverse low libido even in menopausal women and those on antidepressants. This conflicts with Level 1 evidence supporting testosterone therapy for female sexual dysfunction and established physiology of menopause-related genitourinary changes. Women experiencing low desire should have hormone levels and medication side effect profiles clinically evaluated before attributing the issue solely to relational dynamics.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @nadia_bokody actually say?
Bokody, who identifies as an intimacy coach, argues that women in low-sex relationships are wrong to blame their bodies. Her central claim: arousal in women has "very little whatsoever to do with your hormones, your body or your genitals" and "almost everything to do with your brain." She extends this even to menopausal women and those on antidepressants, saying she has watched both groups go from convinced they had no libido to "not being able to keep their hands off their partner." The fix, in her telling, is a partner who makes a woman feel "truly seen, heard and wanted."
The brain-first framing is not invented. It draws loosely on real sex research, particularly Emily Nagoski's work on responsive desire. But Bokody takes that framework and runs it so far past the evidence that the original science would barely recognize it.
Does the science back this up?
Partly, but the parts she overstates are the most medically significant ones. The brain matters enormously for female sexual desire. That is well established. What is not established is that hormones are nearly irrelevant.
Testosterone is the most studied androgen in female sexual function, and the evidence is not ambiguous. A 2019 systematic review and meta-analysis by Davis et al. in The Lancet Diabetes and Endocrinology analyzed 36 randomized controlled trials and found that testosterone therapy significantly improved sexual function in women, including desire, arousal, and frequency of satisfying sexual events. Low estrogen after menopause causes genitourinary syndrome, which directly impairs arousal through physical tissue changes, not through emotional disconnection. Saying hormones have "very little" to do with female arousal contradicts a substantial body of peer-reviewed evidence.
The responsive desire model she references, described by Nagoski in Come As You Are and grounded in work by Basson (2001, Journal of Sex and Marital Therapy), does show that many women experience desire after, not before, sexual context. But even Basson's model does not claim hormones are irrelevant. It accounts for biological factors as one of several inputs.
What did they get wrong (or right)?
She got the relational piece meaningfully right. Feeling emotionally safe, seen, and wanted does affect female desire. This is not pop psychology. Brotto et al. (2016, Journal of Sexual Medicine) found that mindfulness-based interventions targeting attention and psychological safety significantly improved desire and arousal in women with sexual dysfunction. Relationship quality predicts sexual satisfaction across multiple studies. Bokody is correct that many men do not understand how context shapes female desire, and that point deserves credit.
Where she goes badly wrong is in the sweep of the dismissal. Telling menopausal women that their hormones are not the issue is clinically reckless. Menopause involves a dramatic drop in estrogen and testosterone. Genitourinary syndrome of menopause affects roughly 50 percent of postmenopausal women (Portman and Gass, 2014, Menopause) and causes physical changes that make arousal and intercourse genuinely painful or difficult regardless of emotional context. Similarly, SSRIs and SNRIs cause sexual dysfunction through direct pharmacological mechanisms, including delayed orgasm and blunted arousal, not simply because a partner is failing to engage a woman's brain. Coaching cannot reverse serotonin reuptake inhibition.
- Testosterone therapy has Level 1 evidence for improving female sexual desire (Davis et al., 2019, Lancet Diabetes and Endocrinology).
- Menopause-related physical changes are not purely contextual problems.
- Antidepressant sexual side effects have biological mechanisms coaching cannot override.
What should you actually know?
Female sexual desire is genuinely complex, and the brain-body split Bokody draws is a false one. Real clinicians treat both. If your desire has changed, the causes worth ruling out include low testosterone, low estrogen, thyroid dysfunction, medication side effects, depression itself (separate from its treatment), and chronic pain conditions. None of those require you to accept that your relationship is broken or your partner is failing you.
Responsive desire is real and worth knowing about. Many women do not experience spontaneous desire the way it is depicted in media, and that is not pathology. But responsive desire still requires a body that can respond. A woman with untreated genitourinary syndrome, low testosterone, or medication-induced anorgasmia is not going to "not be able to keep her hands off her partner" because her partner started listening better.
The claim that coaching alone reversed low libido even in menopausal and medicated women is unverifiable from a single coach's anecdotal caseload. That is not data. If low desire is affecting your life, a conversation with a clinician who can actually measure your hormone levels and review your medications is a more defensible starting point than assuming the problem is your partner's emotional attunement.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Low libido in women: is testosterone really the missing piece?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Understanding weight gain at menopause
Background source for body-composition and weight-change discussions around menopause.
PubMed
Management of obesity in menopause
Current source for menopause-specific obesity management framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Low libido in women: is testosterone really the missing piece? is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
Bokody's video claims female arousal has 'almost nothing' to do with hormones and that emotional context from a partner can reverse low libido even in menopausal women and those on antidepressants.
FormBlends verdict
Bokody's video claims female arousal has 'almost nothing' to do with hormones and that emotional context from a partner can reverse low libido even in menopausal women and those on antidepressants. This conflicts with Level 1 evidence supporting testosterone therapy for female sexual dysfunction and established physiology of menopause-related genitourinary changes. Women experiencing low desire should have hormone levels and medication side effect profiles clinically evaluated before attributing the issue solely to relational dynamics.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Bokody's video claims female arousal has 'almost nothing' to do with hormones and that emotional context from a partner can reverse low libido even in menopausal women and those on antidepressants. This conflicts with Level 1 evidence supporting testosterone therapy for female sexual dysfunction and established physiology of menopause-related genitourinary changes. Women experiencing low desire should have hormone levels and medication side effect profiles clinically evaluated before attributing the issue solely to relational dynamics.
- A 2019 meta-analysis of 36 RCTs (Davis et al., Lancet Diabetes and Endocrinology) found testosterone therapy significantly improves sexual desire, arousal, and satisfying sexual events in women, directly contradicting the claim that hormones are nearly irrelevant.
- Responsive desire, where desire follows rather than precedes sexual context, is a real and well-documented pattern in women, supported by Basson (2001) and popularized by Nagoski, but it does not mean hormones play no role.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- A 2019 meta-analysis of 36 RCTs (Davis et al., Lancet Diabetes and Endocrinology) found testosterone therapy significantly improves sexual desire, arousal, and satisfying sexual events in women, directly contradicting the claim that hormones are nearly irrelevant.
- Responsive desire, where desire follows rather than precedes sexual context, is a real and well-documented pattern in women, supported by Basson (2001) and popularized by Nagoski, but it does not mean hormones play no role.
- Genitourinary syndrome of menopause affects roughly 50 percent of postmenopausal women and causes physical tissue changes that impair arousal regardless of emotional context or partner behavior.
- SSRIs and SNRIs cause sexual side effects through direct pharmacological mechanisms. These effects often require clinical management, such as dose adjustment, switching agents, or augmentation, not coaching.
- Feeling emotionally safe and desired does influence female sexual desire. Brotto et al. (2016, Journal of Sexual Medicine) found mindfulness and psychological safety interventions significantly improved desire in women with sexual dysfunction.
- Women experiencing low desire should have testosterone, estrogen, and thyroid levels evaluated and have their medication list reviewed before assuming the problem is relational.
- Anecdotal caseloads from a single coach, however large, are not clinical evidence. Uncontrolled observations cannot establish cause and effect or rule out hormonal treatment as the more appropriate intervention.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nadia Bokody · TikTok creator
98.6K views on this video
Its not your libido, babe. #intimacycoachtiktok #intimacy #womenover40 #lowlibido #lowlibidowomen #womenover30 #lowlibidoclub
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Not medical advice. This video was made by Nadia Bokody, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.